- Q2 2024 Medivir AB Earnings Call Transcript5 days agokr2.93Earnings
- Q4 2023 Medivir AB Earnings Call TranscriptFeb 15, 2024kr3.57Earnings
- Medivir AB to Discuss the Updated Data in Advanced Hepatocellular Carcinoma Call TranscriptJan 23, 2024
- Q3 2023 Medivir AB Earnings Call TranscriptOct 27, 2023kr7.35 (+5.00%)Earnings
- Q2 2023 Medivir AB Earnings Call TranscriptAug 18, 2023kr7Earnings
- Q1 2023 Medivir AB Earnings Call TranscriptApr 27, 2023kr7.92Earnings
- Q4 2022 Medivir AB Earnings Call TranscriptFeb 15, 2023kr7.92Earnings
- Medivir AB at Redeye Fight Cancer Day (Virtual) TranscriptJan 19, 2023
- Q3 2022 Medivir AB Earnings Call TranscriptNov 03, 2022kr7.92Earnings
- Q2 2022 Medivir AB Earnings Call TranscriptAug 19, 2022kr8.05Earnings
- Q1 2022 Medivir AB Earnings Call TranscriptApr 28, 2022kr8.05Earnings
- Q4 2021 Medivir AB Earnings Call TranscriptFeb 15, 2022kr8.35Earnings
- Q3 2021 Medivir AB Earnings Call TranscriptNov 03, 2021kr9.99Earnings
- Medivir AB to Discuss Update on the Progress and Plans for the MIV-818 Program Call TranscriptSep 16, 2021
- Q2 2021 Medivir AB Earnings Call TranscriptAug 19, 2021kr10.56 (-5.55%)Earnings
- Q1 2021 Medivir AB Earnings Call TranscriptApr 28, 2021kr7.88Earnings
- Q4 2020 Medivir AB Earnings Call TranscriptFeb 26, 2021kr8.66Earnings
- Medivir AB to Discuss Exclusive Licensing Agreement with IGM Biosciences for Birinapant Call TranscriptJan 12, 2021
- Q3 2020 Medivir AB Earnings Call TranscriptNov 10, 2020kr14.06Earnings
- Q2 2020 Medivir AB Earnings Call TranscriptAug 20, 2020kr16.6Earnings
- Q1 2020 Medivir AB Earnings Call TranscriptMay 05, 2020kr11.44Earnings
- Medivir AB R&D Day TranscriptMar 02, 2020
- Q4 2019 Medivir AB Earnings Call TranscriptFeb 13, 2020kr14.56Earnings
- Q3 2019 Medivir AB Earnings Call TranscriptNov 27, 2019kr21.55Earnings
- Q2 2019 Medivir AB Earnings Call TranscriptAug 28, 2019kr24.68Earnings
- Medivir AB to Discuss the Development of Phase IA Study with MIV-818 Call TranscriptJun 13, 2019
- Q1 2019 Medivir AB Earnings Call TranscriptMay 03, 2019kr19.08Earnings
Medivir AB to Discuss Exclusive Licensing Agreement with IGM Biosciences for Birinapant Call Transcript
Welcome to the Medivir Press conference 2021. (Operator Instructions) We'll try to keep this call to 30 minutes.
Today, I'm pleased to present CEO, Yilmaz Mahshid. Please go ahead of your meeting.
()-&
Thank you, operator, and thank you, everyone, who has called into this call.
Today, we will cover the announcement we did last night, where we entered into exclusive licensing agreement with IGM Biosciences for birinapant.
Next slide, please. So our cautionary statement, it is available on paid. So please take a look at that. Next slide, please. So today's presenter here is me, myself, Yilmaz Mahshid, President and CEO of Medivir, we do also have with us Fred Schwarzer, President and CEO of IGM Biosciences.
We do also have with us our Chief Scientific Officer; Fredrik Ãberg, Medivir, who will be covering the mechanism action of birinapant . Next slide, please. So this is just an executive summer of Medivir. And maybe some new
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)